• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.44% Nasdaq Down0.37%

    NovaBay Pharmaceuticals, Inc. (NBY)

    0.16 Up 0.00(1.20%) Nov 30, 4:02PM EST
    ProfileGet Profile for:
    NovaBay Pharmaceuticals, Inc.
    5980 Horton Street
    Suite 550
    Emeryville, CA 94608
    United States - Map
    Phone: 510-899-8800
    Fax: 510-474-1577
    Website: http://www.novabaypharma.com

    Index Membership:N/A
    Full Time Employees:32

    Business Summary 

    NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes topical non-antibiotic antimicrobial products for the eye care market. It operates through four segments: Dermatology, Ophthalmology, Urology, and Wound Care. The company focuses on addressing the unmet therapeutic needs of the topical anti-infective market. Its commercial products include the Neutrox family of products, including Avenova for the eye care market; Neutrophase for wound care; and CelleRx for the dermatology market. The company’s products under development stage consist of Aganocide compounds, which are novel, synthetic anti-infectives designed to mimic the body’s defense against infection and developed to treat and prevent a range of local, non-systemic infections with a low likelihood of developing bacterial resistance. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds that cover various dermatological conditions. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on NovaBay Pharmaceuticals, Inc.

    Key Executives 
    Mr. Mark M. Sieczkarek , 60
    Chairman, Interim Chief Exec. Officer, Interim Pres, Chairman of Compensation Committee and Member of Nominating and Corp. Governance Committee
    Mr. Thomas J. Paulson M.B.A., 68
    Chief Financial Officer, Treasurer and Sec.
    Mr. Roy J. Wu M.B.A., 60
    Sr. VP of Bus. and Corp. Devel.
    Dr. David W. Stroman Ph.D., 70
    Chair of The Ophthalmology Advisory Board and Sr. VP of Ophthalmic Product Devel.
    Mr. Glenn Moro ,
    VP of Sales and Marketing for Avenova
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders